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The increase in pulmonary capillary pressure due to LHD is a triggering event leading to physical
and biological alterations of the pulmonary circulation. Acutely, mechanosensitive endothelial
dysfunction and increased capillary permeability combinedwith reduced fluid resorption lead to
the development of interstitial and alveolar oedema. From repeated cycles of such capillary
stress failure originatemore profound changeswith pulmonary endothelial dysfunction causing
increased basal and reactive pulmonary vascular tone. This contributes to pulmonary vascular
remodelling with increased arterial wall thickness, but most prominently, to alveolar wall
remodelling characterized by myofibroblasts proliferation with collagen and interstitial matrix
deposition. Although protective against acute pulmonary oedema, alveolar wall thickening
becomesmaladaptive and is responsible for the development of a restrictive lung syndrome and
impaired gas exchanges contributing to shortness of breath and PH. Increasing awareness of
these processes is unraveling novel pathophysiologic processes that could represent selective
therapeutic targets. Thus, the roles of caveolins, of the intermediate myofilament nestin and of
endothelial calcium dyshomeostasis were recently evaluated in pre-clinical models. The
pathophysiology of PH due to LHD (group II PH) is distinctive from other groups of PH. Therefore,
therapies targeting PH due to LHDmust be evaluated in that context.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Pulmonary hypertension
Heart failure
Lung remodelling
Vascular endothelium
PathophysiologyThe most prevalent cause of pulmonary hypetension (PH) is
left-sided heart disease (LHD), classified as group 2 PH.
Although clinicians are well aware of the negative functional
and vital prognostic impact of PH in heart failure with reduced
ejection fraction (HFrEF) and heart failure with preservede 18.
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therapies to selectively target and treat group 2 PH. A better
understanding of the pathophysiologic processes leading to
group 2 PH is imperative. We will review the current
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Abbreviations and Acronyms
EDHF = endothelial-derived
hyperpolarizing factors
Cav-1 = caveolin-1
eNOS = endothelial nitric
oxide synthase
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
HFpEF = heart failure with
preserved ejection fraction
IEL = internal elastic lamina
LHD = left-sided heart disease
NO = nitric oxide
PAH = pulmonary arterial
hypertension
PH = pulmonary hypertension
PDGF = platelet-derived
growth factor
PGI2 = prostacyclin
ET-1 = endothelin-1
VEGF = vascular endothelium
growth factor
VIP = vasoactive intestinal
peptide
PDE2 = phophodiesterase E2
L-NAME = L-NG-Nitroarginine
methyl ester
TRPV4 = transient receptor
potential vanilloid 4
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and the reactive bio-
logic alterations lead-
ing to lung structural
andarteriolarremodelling.Functional structure
of the pulmonary
vasculature
The normal pulmonary
vasculature, a low-pressure
low-resistance system
compared to the sys-
temic circulation, is
capable of accommo-
dating large increases
in blood flow with mini-
malelevation inpressure.
Pulmonary arteries and
arterioles are thin-walled
compared their systemic
counterparts. In addition
to luminal diameter, the
extent of contribution of
the artery to pulmonary
resistance is based on
structural features, the
cellular composition of
each of the wall layers as
well as fibrotic content.1
The tunica intima
of the pulmonary vas-
culature at the alveo-
lar capillary level is
responsible for assur-
ing optimal gas ex-
change while limiting
the flux of fluid andmacromolecules to the alveolar and interstitial spaces.
Pulmonary vascular endothelial cells share a number of
markers with endothelial cells of other vascular beds, but
differ in their morphology and express pulmonary-specific
markers and proteins like angiotensin I converting enzyme
(ACE) and human lung endothelial-cell-specific molecule-1
promoter (ESM-1),2 due to their role as well as the low
pressure and flow conditions within the pulmonary
circulation.3,4 Moreover, pulmonary endothelial cells differ
between the macro and microcirculation of the lung in their
shape, their mechanosensing properties, glycocalyx structure,
caveolae density5,6 as well as ion channel expression and
function. For example, pulmonary microvascular endothelial
cells express a number of calcium channels that are not found
in extra-alveolar endothelial cells.7
The tunica media or smooth muscle layer of pulmonary
arteries is also much thinner compared their systemic
counterparts of similar luminal diameter. The degree of
muscularization of the tunica media varies with pulmonaryvessel diameter.8 Additionally, the extent of elastic laminae
thickness changes with vessel size: as arterial lumen diame-
ter decreases down the pulmonary vascular tree, the elastic
laminae become less prominent and are replaced by smooth
muscle cells.8 The internal elastic lamina (IEL) of arteries is
studded with holes (fenestrations) that permit endothelial
cell-smooth muscle cell communication. This communica-
tion is enabled by the presence of endothelial cell/smooth
muscle cellular extensions through those fenestrations,
termed myoendothelial projections. Studies on pulmonary
arteries have reported modifications in IEL structure and
composition, as well as changes in the number of gaps in the
IEL in several cardiovascular diseases including PH.9,10 Finally,
the nature of endothelium-derived factors that control
pulmonary vascular tone, as well as the extent of their
relative contribution differ along the pulmonary vascular tree.Endothelial control of the pulmonary circulation:
Mechanisms of regulation of pulmonary vascular tone
Endothelial influence on pulmonary vascular function is
inferred through mechanisms and substances with vasocon-
strictor/vasodilator properties and modulating growth and
proliferation of cells within the vessel wall. The pulmonary
circulation has a low resting tone under normal conditions.
Pulmonary vascular endothelial cells control tone through
numerous pathways and molecules like nitric oxide (NO),
endothelium-derived hyperpolarizing factor (EDHF), prosta-
cyclin (PGI2), endothelin-1 (ET-1) as well as many additional
factors including platelet-derived growth factor (PDGF), vascular
endothelium growth factor (VEGF), vasoactive intestitinal pep-
tide (VIP), urotensin, adrenomedullin and leukotrienes. In
addition, the pulmonary vascular endothelium is an important
site for metabolism and clearance of circulating mediators such
as angiotensin-I, endothelin, serotonin, adrenomedullin, and
many others through specific receptors, enzymes and
transporters.11–17 The pulmonary endothelium will therefore
modulate local, but also systemic vascular biology. This review
will restrict its focus to some of the pathways that may be more
relevant to PH associated with LHD. It is generally recognized
that endothelial dysfunction is a core abnormality contributing
to all forms of PH, including group II PH. Current therapies
approved for group I PH all target endothelial products or
properties: prostacyclin and its analogs, PDE2 inhibitors,
endothelin receptor antagonists, soluble guanylate cyclase
stimulators. One notable exception is calcium channel blockers,
targeting the smooth muscle cell, that are very effective for the
treatment of vasoreactive PH, a rare form of group I PH with a
good prognosis. None of these PH therapies are however
currently approved for PH due to LHD (group II PH).
Nitric oxide pathway
Extensive work has established the role of the NO pathway in
background mechanisms preserving basal pulmonary vascu-
lar tone. Animal model studies showed involvement of NO in
the maintenance of a lower basal pulmonary vascular tone.18
By using nitric oxide synthase inhibitors such as L-NAME in
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resting pulmonary vasorelaxation.19–22 These investigations
revealed a prominent but partial role for NO in opposing
increases in tone; a role that seems to be more pronounced in
large conduit arteries compared to smaller resistance vessels.
Basal constitutive expression of eNOS (NOSIII) in pulmonary
vascular endothelium has been reported23,24 and is essential
for a sustained low pulmonary vascular pressure.22
Moreover, subcellular distribution of the enzyme appears
critical to its activity. Indeed, Cav-1 binding to the calmodulin-
binding site of eNOS leads to the enzyme uncoupling and
incapacity to produce NO, therein located within caveolae.25–27 As
we will discuss later, caveolins seem to play a key role in the
maintenance of pulmonary microcirculatory homeostasis.28
Prostacyclin (PGI2)
PGI2 ismetabolized fromarachidonic acid through the cyclooxygen-
ase pathway (COX). Endothelial production and release of PGI2
causes vasodilation of underlying smoothmuscle cells by stimulat-
ing cyclic adenosine monophosphate (cAMP) formation. In the
normal pulmonary circulation, PGI2 was shown to be a contributor
to basal pulmonary vascular tone inanumberof animal studies.29,30
Several types of prostanoid receptors, including the PGI2 receptors
(IP) that control pulmonary vascular tone have been identified in
mice lungs.31 Additionally, a number of human and animal studies
demonstrated that stimulationofadenylate cyclaseand theensuing
increase in smooth muscle cAMP levels lead to the opening of K+
channels and pulmonary vasodilation.32,33
Endothelial-derived hyperpolarizing factors
EDHF consists of an amalgam of mechanisms (excluding NO
and PGI2) of endothelial origin leading to hyperpolarization of
vascular smooth muscle cells. These mechanisms can involve
either direct electrical coupling through myoendothelial com-
munication or the release of factors that directly influence
myocyte membrane potential such as K+ clouds (spatially
restricted accumulation of K+ ions in the intercellular space).
The nature of these mechanisms and factors and their
respective contribution to the regulation of vascular tone varies
with arterial diameter and the species studied. It consists in a
wide range of proteins, molecules and mechanisms including
small and intermediate calcium-activated potassium channels
(KCa2.x and KCa3.1), connexins, epoxyeicosatreionic acids (EETs;
metabolites of arachidonic acid), hydrogen peroxide (H2O2), and
C-type natriuretic peptide. Similarly to NO, the role of EDHF in
the maintenance of low resting pulmonary vascular tone has
been established.34,35 Animal models aided in demonstrating
the participation of EDHF in the regulation of pulmonary tone
through cytochrome P450 metabolites or activation of small
and intermediate Ca2+-activated K+ channels.36–38 Unlike NO,
the role of EDHF was found to be more pronounced in the
pulmonary microcirculation compared to larger vessels.39,40
Endothelin (ET)
ET-1 is the predominant isoform of this potent vasoconstrictor
and proliferator peptide produced by endothelial cells. ETreceptors are present on both vascular endothelial (ETB) and
smoothmuscle cells (ETA and ETB).41 Stimulation of endothelial
ETB receptor causes pulmonary vasodilation while the smooth
muscle ETA and ETB receptors promote vasoconstriction and
proliferation.42 The endothelial ETB is responsible for clearance
of circulating ET-1, suggesting that the lungs are a primary
target of this peptide.15 Furthermore, pulmonary artery smooth
muscle ET receptors can form heterodimers, modifying their
pharmacological response.43,44 In healthy humans, endothelin
influences pulmonary vasomotor tone in physiological states,19,45,46
and its modulatory role is greatly increased in pathological
conditions as discussed in later sections.
Endothelial dysfunction is a great contributor to pulmonary
vascular tone alterations, and potentially to pulmonary vascu-
lar remodelling. An improved understanding of pulmonary
vascular alterations that contribute to PH in LHD and how it
differs from group I PH is required. Fig 1 summarizes the factors
that contribute to the control of normal pulmonary vascular
tone. The remaining of this review discusses pathological
alterations of the pulmonary circulation of group II PH.Lung capillary injury in LHD
Shortness of breath, the cardinal clinical symptomofHF, occurs
when pulmonary capillary pressure increases due to LHD.
Backward transmission of elevated left heart filling pressure to
pulmonary veins is in turn transferred to pulmonary capillaries.
Consequent alteration of the capillary hydrostatic/oncotic
pressures balance promotes augmented passage of fluid across
the alveolar-capillary barrier according to the Starling principle.
This accumulation of fluid within the interstitial space and
ultimately into alveoli is accompanied by a decreased clearance
with eventual physical disruption of the alveolar-capillary
barrier; a phenomenon termed capillary stress failure.47,48 A
recent study, suggested that increased intracellular calcium
levels of lung microvascular endothelial cells causes endothe-
lial retraction thus increasing capillary permeability and
promoting oedema.49 Indeed, pathological and pharmacologi-
cal activation of calcium channels expressed in capillary
endothelial cells was found to promote vascular leakage
through alveolar-capillary membranes.50–52 Resorption of alve-
olar fluid occurs through the amiloride-sensitive alveolar
epitheliumsodiumchannel (ENaC)53 and lung sodiumhandling
is impaired in human subjects after myocardial infarction,54
further contributing to the development of alveolar oedema.
Studies support an important role for activation of the Ca2+-
permeable transient receptor potential vanilloid 4 (TRPV4)
channels in hydrostatic pulmonary edema.52,55 Transgenic
deletion of this mechano-sensitive channel appears to protect
from hydrostatic pulmonary edema56 and pharmacological
blockade effectively prevents and treats pulmonary oedema in
acute and chronic heart failure (HF) models.55
Repetitive and sustained elevations in pulmonary capillary
pressure, resulting from recurrent retrograde increases in left
ventricular pressure, will induce a series of injury-repair cycles
to the capillary wall. Initiation of capillary remodelling, along
with increased fluid clearance57 is protective mechanisms
against pulmonary oedema in patients with chronic HF.58,59
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efficiency and the associated gas exchange, thus further contrib-
uting to disease progression.58 Studies on both animal models
and humans have shown collagen deposition and alveolar septa
thickening accompanied by cellular proliferation58,60–65 thatwere
associated with reduced alveolar capillary permeability and
correlated with a diminished respiratory function in HF. Addi-
tionally, a study using an aortic banding-induced HF model
demonstrated calcium handling-related cytoskeletal disorgani-
zation contributing to alveolar-capillary remodelling.66Abnormal vascular reactivity in PH associated
with LHD
Dysregulation of pulmonary vascular tone in PH has been
established through a number of studies that mainly focused
on NO-, ET-1-, PGI2-, and EDHF-dependent pathways. Rat
models of congestive heart failure showed an impaired
NO-dependent vasodilator response in pulmonary arteries67
and elevated sustained levels of ET-1 involved in alterations
of vascular reactivity.44,68,69
Human patient studies revealed that endothelial dependent
vasodilation was impaired due to deficient basal production of
NO. These findings strongly suggested that the loss of
NO-dependent vasodilation contributes to the development of
PH.23,67 The concomitant role of the endothelin system in the
development of PH was previously reviewed in detail.42,70 In aFig 1 – Biologic functions of the endothelial and muscular layers
produced, transformed or inactivated by the pulmonary vascular
expressed by endothelial and vascular smooth muscle cells. Nitr
(EDHF); prostacyclin (PGI2); angiotensin-converting enzyme (ACE
angiotensin 1 receptor (AT1); bradykinin (Bk); cyclo-oxygenase (C
receptors (ETA, ETB); endothelin-1 (ET-1); L-arginine (L-Arg); pros
serotoninergic receptor (S1); thrombox-ane receptor (TH); thromb
receptor (OR); calcitonin receptor-like receptor-receptor activity m
neurokinin receptor (NK-1); substance P (SP); vasoactive intestina
aminopeptidase P (AP-P); norepinephrine transporter (NET); nore
receptor (IP); transient receptor potential vanilloid channel 4 (TRP
reticulum Ca2+-ATPase (SERCA); endoplasmic reticulum (ER); sm
2.3); intermediate conductance calcium-activated potassium cha
channel (Kir); sodium/potassium triphosphatase pump (Na+/K+).number of human HF studies, elevation in circulating levels
of ET-1 was found71,72 and correlated especially well with
increased pulmonary artery pressure73 and worse prognosis.74
Accordingly, endothelin receptor antagonists selectively reduce
pulmonary vascular resistance in HF.75 Cross-talks between
endothelin and NO systems occur as chronically increased ET
levels reduce pulmonary vascular reactivity to NO.41 However,
other mechanisms are potentially involved in pulmonary
vascular reactivity in HF including PGI2- and EDHF-associated
pathways. A potential role for EDHF in endothelium-dependent
relaxation has been suggested fromanumber of animalmodels
of HF.76 In a caninemodel of pacing-induced HF, a disruption of
receptor-mediated stimulation of adenylate cyclase was ob-
served, alongwith a depressed dilatory response to arachidonic
acid and PGI2.77 Intravenous administration of prostaglandin E1
in patientswithmitral valve disease or congenital heart disease
resulted in a significant fall in pulmonary arterial pressure.78,79
Moreover, clinical studies on inhaled vasodilators like Epoprostenol
or Iloprost (prostacyclin PGI2 analogs) validated impaired PGI2-
associated endothelium-dependent vasodilation in group 2 PH.80–82Remodelling process of small pulmonary arteries
Although less prominent than in other types of PH, lung
vascular remodelling contributes to increased pulmonary
vascular resistance (PVR) in PH due to LHD. A study by
Delgado and colleagues conducted on a group of heartof the pulmonary vasculature. Various mediators are
endothelial cells. Specific receptors and transporters are
ic oxide (NO); endothelium-derived hyperpolarizing factor
); acetylcholine (Ach); angiotensin I (AI); angiotensin II (AII);
OX); endothelin-converting enzyme (ECE); endothelin A and B
taglandin H2 (PGH2); reactive oxygen species (ROS);
in (Thr); thromboxane A2 (TXA2); serotonin (5-HT); opioid
odifying protein (CRLR-RAMP); adrenomedullin (AM);
l peptide receptor (VPAC); vasoactive intestinal peptide (VIP);
pinephrine (NE); serotonin transporter (5-HTT); prostacyclin
V4); inositol triphosphate receptor (IP3R); sarco/endoplasmic
all conductance calcium-activated potassium channel 3 (KCa
nnel (KCa 3.1); connexin (Cx); inward rectifiying potassium
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validated pulmonary vascular remodelling as a determining
factor for the severity of PH in right ventricular failure after
heart transplantation.83 Intravascular ultrasound further
documented pulmonary vascular remodelling in patients
with PH subsequent to LHD. Pulmonary medial hypertrophy
and smaller intraluminal diameter were reported to be more
pronounced in lower lobes and to correlate with pulmonary
artery pressure and elevated plasma ET-1 levels.84 Prepon-
derant alterations found in the lower lobes, more sensitive to
gravitational forces, suggest the importance of chronically
increased capillary hydrostatic pressures as an initiating
event.84 Although changes in the pulmonary vessels with
medial hypertrophy contribute to PH due to LHD, these
alterations appear milder than those found in group I PH.
Indeed, tunica media thickening of small pulmonary arteries
(50–200 μM diameter) from rats with systolic HF was only of
4–5%. In larger pulmonary arteries from the samemodels there
was also medial hypertrophy with increased collagen and
elastin content.85 The uniqueness of group II PH remodelling
therefore resides, at least partially, in the changes occurring in
the alveolar vessels and pulmonary veins.Endothelial dysfunction and calcium
dyshomeostasis in PH associated with LHD
Both systemic and microvascular pulmonary endothelial
dysfunction are present in HF and the former most likely
impacts the latter. In a recent study by Farrero et al.86
peripheral endothelial dysfunction was shown to directly
correlate with PVR in patients with HFpEF. This work
identified endothelial dysfunction and abnormal collagen
metabolism as markers in identifying patients with HFpEF at
risk of developing PH. Pulmonary arteries from rats with
compensated systolic HF were characterized with an endothelial
dysfunction from a reduced NO production (both basal and
stimulated) and decreased eNOS expression.85
Variations in [Ca2+]i are central to a multitude of cellular
processes, including the genesis of various endothelial
factors.87 Endothelial [Ca2+]i regulation is thus a highly
dynamic requiring finely tuned processes that involve a
broad range of molecules, receptors, calcium-permeable
channels36,88 and anchoring proteins. Intracellular endothelial
calcium signalling should however be considered froma spatial
perspective, with global and local calcium signalling. In regards
to global calcium signalling, the well-established activation of
G-protein coupled receptors leads to the mobilization of a G
protein subunit and theproduction of inositol triphosphate (IP3)
through the action of phospholipase C (PLC). The ensuing
activation of IP3 receptors evokes calcium release from the
endoplasmic reticulum (ER). Propagated activation of numer-
ous neighbouring IP3 receptors triggers a massive Ca2+ release
in the cytoplasm, also causing ER depletion and activation of
the store-operated calcium entry (SOCE) pathways, responsible
of a sustained elevated cytosolic calcium level. This substantial
increase in [Ca2+]i non-selectively activates a myriad of
pathways involved for example in the control of vascular tone
(NO, PGI2, and EDHF), and vascular remodelling. In a rat modelof HFpEF through aortic banding, pulmonary endothelial
calcium impairmentwas shown to be associated to cytoskeletal
reorganization anddisruption of normal endothelial function.66
In addition, dysfunctional pulmonary arterial function and
structurewere linked tomodified calcium-permeable channels.89
For instance, intracellular calcium regulation through TRPV4
channels is involved in the vascular permeability response to
increased pulmonary vascular pressure.56 Accordingly, it was
demonstrated that inhibition of PDE5 constitutes a negative
feedback loop that attenuates pressure-induced [Ca2+]i increase
within pulmonary capillaries.90
Local calcium signalling, on the other hand, consists of
spontaneous and spatially restricted intracellular calcium
oscillations. Several local calcium signals have been charac-
terized, mainly based on their specific intracellular localiza-
tion and kinetic. Spatial restriction of intracellular calcium
dynamics confers significant benefits: specific modulation of
calcium-sensitive signalling pathways within a defined intra-
cellular region without affecting other cellular functions and
in a highly efficient manner, on an energetic perspective.
Spontaneous and propagating calcium increases in pulmo-
nary microvascular cells termed calcium waves were
reported.91 Furthermore, pressure-induced calcium oscilla-
tions were studied in pulmonary capillaries.92 Local endothe-
lial calcium signalling in PH associated with LHD remains
however to be characterized. Our team recently reported for
the first time the presence of local endothelial calcium
transients termed calcium pulsars in intact small pulmonary
arteries using GCaMP-2 transgenic mice.93 Interestingly,
TRPV4 channels are major modulator of these calcium events.
Exploring kinetic properties of those transients in the context
of group 2 PH may unveil a significant role for those events in
alterations of pulmonary vascular tone and/or a potential
novel therapeutic avenue.Lung alveolar wall remodelling: A central role
for myofibroblasts
In HF, lung capillary injury and subsequent inflammation
with activation of neurohumoral mediators cause the activa-
tion and proliferation of myofibroblats.58,60–63 Myofibroblasts
proliferate into the alveolar wall in response to lung injury
and secrete collagen and interstitial matrix components
protecting against development of pulmonary oedema. How-
ever this process can become maladaptive and trigger a
restrictive lung syndrome that manifests through reduced
compliance and impaired gas exchange. Fig 2 demonstrates
examples of histologic findings in the lungs from a human
subject with LHD and a mouse with LHD induced by coronary
artery ligation. Similar histological changes are seen with
obvious thickening of the alveolar septa resulting from
myobroblasts proliferation and collagen deposition. Further
characterization of alveolar wall remodelling in rats with
HF was performed by electron microscopy and showed
myofibroblasts proliferation with collagen, elastin and reticulin
deposition, thickening of basement membranes and increased
formation of basement membrane-like material in the alveolar
wall (Fig 3).61 Anumber of studies using different animalmodels
Fig 2 –Histologic examples of lung remodelling in animals and humanswith LHD usingwithMasson's trichrome staining (A–F)
and immunostaining for smooth muscle alpha-actin (G–H). Normal sham operated mice (A, C) are compared with mice with
LHD 3 weeks after coronary artery ligation (B, D). There is important thickening of the alveolar septa in LHD with increased
collagen content (blue) in alveolar and vessel walls. A human subject with LHD due to chronic ischemic cardiomyopathy (F)
shows thickening of the alveolar wall with important collagen deposition compared to a subject without LHD (E). Compared to a
control subject (G), immunostaining of smooth muscle alpha actin in a human subject with LHD due to aortic stenosis shows
medial vascular hypertrophy and aveolar wall cells expressing the smooth muscles marker representing myofibroblasts (H).
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revealed the contribution of bone marrow-derived progenitor
cells,94 as well as resident lung mesenchymal cells.95 Amongst
potentially relevant factors involved in pulmonary remodelling andmyofibroblasts proliferation are reduced caveolins expression28 and
increased angiotensin-II levels.61,96 Caveolin KO rats develop lung
alveolarwall remodelling similar to that seen in LHD.28 Angiotensin
receptors are expressed in lung myofibroblasts and their activation
Fig 3 – Electron microscopy of lung sections from 2-week sham operated rats (a, b) and 2-week LHD rats induced by coronary
artery ligation (c, d). (b) and (d) represent an 10Xmagnification of the squared region from picture (a) and (c) respectively. In the
MI group there is thickening of the alveolar septum due to enlargement of the basal membrane, deposition of collagen and
elastin and cellular proliferation. A, indicates alveoli; B, basal membrane; BLM, basal membrane-like material; C, capillaries;
Co, collagen; EC, endothelial cells; El, elastin; L, lymphocyte; P, pericyte; Pn, type I pneumocyte; PnII, type II pneumocyte;
M, macrophage. Reproduced with permission from Cardiovasc Res, 2003. 58(3): p. 621–31.
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tensin receptor antagonist irbesartan efficiently prevented lung
remodelling in rats with HFrEF.61 More recently, increased
expression of the intermediate filament protein nestin wasLung remodelling in
lung capillary pressure
Mechanosensitive endothelial dysfunction
Increased capillary permeability
   flud  resorption
Bronchial congestion
Interstitial and
alveolar   oedema
acute
Repair and restitutio
ad integrum P
Fig 4 – Pathophysiology of lung vascular and sreported in lung myofibroblasts in HFrEF, even preceding PH
development.97 Nestin expression also seems to play a role in
endothelial/epithelial cell transition to amesenchymal phenotype
in the fibrotic PH lungs.98 left heart diseases
Chronic
Endothelial dysfunction
Myofibroblasts proliferation
Alveolar wall remodelling
Pulmonary vascular remodelling
Pulmonary vascular resistance
Alveolar wall thickening
Protective Maladative
ulmonary oedema
Restrictive lung syndrome
Reduced gas exchanges
Pulmonary hypertension
tructural remodelling associated with LHD.
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ical treatments efficiency in the reversal of adverse effects ofHFon
alveolar remodelling. For instance, PDE5 inhibition with Sildenafil
showedpromise in clinical studies as it improvedexercise capacity
and gas exchanges.99,100 However, although many group I PH
selective therapies including sildenafil were evaluated in HF, none
had similar beneficial outcomes in group II PH. These previous
studies were however not initially designed to specifically address
group II PH and stratification was not established because study
subjects were not stratified according to the presence of PH or the
impact of lung remodelling. In contrast, very encouraging
pre-clinical studies evaluating the effect of angiotensin receptor
blockers61 and atorvastatin101 report an impressive reduction of
lung structural remodelling and pulmonary hypertension associ-
ated with HF. Some PH specific therapies such as endothelin
receptor antagonists however did not show benefit in pre-clinical
models of systolic HF.102 Fig 4 summarizes the pathophysiology of
lung structural and vascular remodelling in LHD.Conclusion
LHD directly physically impacts the pulmonary circulation
through increased hydrostatic pressure with combined reduced
alveolar resorption leading to pulmonary edema. Recurrent cycles
of lung capillary injury and repair associated with pulmonary
vascular endothelial dysfunction result in increased pulmonary
vascular tone, pulmonary vascular remodelling and alveolar wall
remodelling. Myofibroblasts proliferation, with concomitant depo-
sition of collagen, plays a key role in alveolar wall thickening. This
initially protective mechanism eventually leads to a restrictive
lung syndrome and impaired gas exchange, further contributing
to PH. Abnormal global and local pulmonary endothelial Ca+
signalling in HF requires better pathophysiological characteriza-
tion. Substantial effort is currently being invested into unveiling
the pathophysiological mechanisms underlying the development
of PH in LHD. Extensivework is still needed but further elucidation
of vascular changes and the herein mechanisms might signifi-
cantly improve our capacity to reverse, limit the progression of the
pathology or alleviate its symptoms.Statement of conflict of interest
None of the authors have any conflicts of interests with regard
to this publication.
Acknowledgements
The authorswould like to thankDrMartin Sirois andMarie-Élaine
Clavet for the histology service provided onmouse lung sections.
R E F E R E N C E S
1. Wang Z, Chesler NC. Pulmonary vascular wall stiffness: An
important contributor to the increased right ventricular
afterload with pulmonary hypertension. Pulm Circ. 2011;1(2):
212-223.2. Tsai JC, Zhang J, Minami T, et al. Cloning and characterization
of the human lung endothelial-cell-specific molecule-1
promoter. J Vasc Res. 2002;39(2):148-159.
3. Aird WC. Mechanisms of endothelial cell heterogeneity in
health and disease. Circ Res. 2006;98(2):159-162.
4. Aird WC. Phenotypic heterogeneity of the endothelium: I.
Structure, function, and mechanisms. Circ Res. 2007;100(2):
158-173.
5. King J, Hamil T, Creighton J, et al. Structural and functional
characteristics of lungmacro- andmicrovascular endothelial
cell phenotypes. Microvasc Res. 2004;67(2):139-151.
6. Zhou C, Chen H, King JA, et al. Alpha1G T-type calcium
channel selectively regulates P-selectin surface expression
in pulmonary capillary endothelium. Am J Phys Lung Cell Mol
Phys. 2010;299(1):L86-L97.
7. Stevens T. Functional and molecular heterogeneity of
pulmonary endothelial cells. Proc Am Thorac Soc. 2011;8(6):
453-457.
8. Townsley MI. Structure and composition of pulmonary
arteries, capillaries, and veins. Compr Phys. 2012;2(1):675-709.
9. Aiello VD, Gutierrez PS, Chaves MJ, et al. Morphology of the
internal elastic lamina in arteries from pulmonary
hypertensive patients: a confocal laser microscopy study.
Mod Pathol. 2003;16(5):411-416.
10. Lam CF, Peterson TE, Croatt AJ, et al. Functional adaptation
and remodeling of pulmonary artery in flow-induced
pulmonary hypertension. Am J Physiol Heart Circ Physiol.
2005;289(6):H2334-H2341.
11. Dupuis J, Goresky CA, Ryan JW, et al. Pulmonary
angiotensin-converting enzyme substrate hydrolysis during
exercise. J Appl Physiol. 1992;72(5):1868-1886.
12. Dupuis J, Goresky CA, Stewart DJ. Pulmonary removal and
production of endothelin in the anesthetized dog. J Appl
Physiol. 1994;76(2):694-700.
13. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of
circulating endothelin-1 in dogs in vivo: exclusive role of ETB
receptors. J Appl Physiol. 1996;81(4):1510-1515.
14. Dupuis J, Goresky CA, Rouleau JL, et al. Kinetics of pulmonary
uptake of serotonin during exercise in dogs. J Appl Physiol.
1996;80(1):30-46.
15. Dupuis J, Stewart DJ, Cernacek P, et al. Human pulmonary
circulation is an important site for both clearance and
production of endothelin-1. Circulation. 1996;94(7):1578-1584.
16. Langleben D, Dupuis J, Langleben I, et al. Etiology-specific
endothelin-1 clearance in human precapillary pulmonary
hypertension. Chest. 2006;129(3):689-695.
17. Dupuis J, Caron A, Ruel N. Biodistribution, plasma kinetics
and quantification of single-pass pulmonary clearance of
adrenomedullin. Clin Sci (Lond). 2005;109(1):97-102.
18. Koizumi T, Gupta R, Banerjee M, et al. Changes in pulmonary
vascular tone during exercise. Effects of nitric oxide (NO)
synthase inhibition, L-arginine infusion, and NO inhalation. J
Clin Invest. 1994;94(6):2275-2282.
19. Cooper CJ, Landzberg MJ, Anderson TJ, et al. Role of nitric
oxide in the local regulation of pulmonary vascular resis-
tance in humans. Circulation. 1996;93(2):266-271.
20. Stamler JS, Loh E, Roddy MA, et al. Nitric oxide
regulates basal systemic and pulmonary vascular
resistance in healthy humans. Circulation. 1994;89(5):
2035-2040.
21. Celermajer DS, Dollery C, Burch M, et al. Role of endothelium
in the maintenance of low pulmonary vascular tone in
normal children. Circulation. 1994;89(5):2041-2044.
22. Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impair-
ment of endothelium-dependent pulmonary-artery
relaxation in chronic obstructive lung disease. N Engl J Med.
1991;324(22):1539-1547.
19P R O G R E S S I N C A R D I O V A S C U L A R D I S E A S E S 5 9 ( 2 0 1 6 ) 1 1 – 2 123. Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary
hypertension in chronic heart failure: the role of the
endothelium in pathophysiology and management.
Circulation. 2000;102(14):1718-1723.
24. Kobzik L, Bredt DS, Lowenstein CJ, et al. Nitric oxide synthase
in human and rat lung: immunocytochemical and histo-
chemical localization. Am J Respir Cell Mol Biol. 1993;9(4):
371-377.
25. Grayson TH, Chadha PS, Bertrand PP, et al. Increased
caveolae density and caveolin-1 expression accompany
impaired NO-mediated vasorelaxation in diet-induced
obesity. Histochem Cell Biol. 2013;139(2):309-321.
26. Feron O, Saldana F, Michel JB, et al. The endothelial
nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem.
1998;273(6):3125-3128.
27. Frank PG, Woodman SE, Park DS, et al. Caveolin, caveolae,
and endothelial cell function. Arterioscler Thromb Vasc Biol.
2003;23(7):1161-1168.
28. Jasmin JF, Mercier I, Hnasko R, et al. Lung remodeling and
pulmonary hypertension after myocardial infarction: path-
ogenic role of reduced caveolin expression. Cardiovasc Res.
2004;63(4):747-755.
29. Frantz E, Soifer SJ, Clyman RI, et al. Bradykinin produces
pulmonary vasodilation in fetal lambs: role of prostaglandin
production. J Appl Phys (1985). 1989;67(4):1512-1517.
30. Gryglewski RJ, Chlopicki S, Uracz W, et al. Significance of
endothelial prostacyclin and nitric oxide in peripheral and
pulmonary circulation. Med Sci Monit. 2001;7(1):1-16.
31. Olschewski A, Olschewski H, Brau ME, et al. Basic electrical
properties of in situ endothelial cells of small pulmonary
arteries during postnatal development. Am J Respir Cell Mol
Biol. 2001;25(3):285-290.
32. Schubert R, Serebryakov VN, Engel H, et al. Iloprost activates
KCa channels of vascular smooth muscle cells: role of
cAMP-dependent protein kinase. Am J Phys. 1996;271(4 Pt 1):
C1203-C1211.
33. Jones RL, Qian Y, Wong HN, et al. Prostanoid action on the
human pulmonary vascular system. Clin Exp Pharmacol
Physiol. 1997;24(12):969-972.
34. Feletou M, Girard V, Canet E. Different involvement of nitric
oxide in endothelium-dependent relaxation of porcine
pulmonary artery and vein: influence of hypoxia. J Cardiovasc
Pharmacol. 1995;25(4):665-673.
35. Hasunuma K, Yamaguchi T, Rodman DM, et al. Effects of
inhibitors of EDRF and EDHF on vasoreactivity of perfused rat
lungs. Am J Phys. 1991;260(2 Pt 1):L97-104.
36. Sukumaran SV, Singh TU, Parida S, et al. TRPV4 channel
activation leads to endothelium-dependent relaxation
mediated by nitric oxide and endothelium-derived
hyperpolarizing factor in rat pulmonary artery. Pharmacol
Res. 2013;78:18-27.
37. Karamsetty MR, Nakashima JM, Ou L, et al. EDHF contributes
to strain-related differences in pulmonary arterial relaxation
in rats. Am J Phys Lung Cell Mol Phys. 2001;280(3):L458-L464.
38. Fuloria M, Smith TK, Aschner JL. Role of
5,6-epoxyeicosatrienoic acid in the regulation of newborn
piglet pulmonary vascular tone. Am J Phys Lung Cell Mol Phys.
2002;283(2):L383-L389.
39. ZouW, Yang Q, Yim AP, et al. Impaired endothelium-derived
hyperpolarizing factor-mediated relaxation in porcine pul-
monary microarteries after cold storage with Euro-Collins
and University of Wisconsin solutions. J Thorac Cardiovasc
Surg. 2003;126(1):208-215.
40. Zhang RZ, Yang Q, Yim AP, et al. Role of NO and
EDHF-mediated endothelial function in the porcine
pulmonary circulation: comparison between pulmonary
artery and vein. Vasc Pharmacol. 2006;44(3):183-191.41. Migneault A, Sauvageau S, Villeneuve L, et al. Chronically
elevated endothelin levels reduce pulmonary vascular
reactivity to nitric oxide. Am J Respir Crit Care Med.
2005;171(5):506-513.
42. Michel RP, Langleben D, Dupuis J. The endothelin system in
pulmonary hypertension. Can J Physiol Pharmacol. 2003;81(6):
542-554.
43. Sauvageau S, Thorin E, Caron A, et al. Endothelin-1-Induced
Pulmonary Vasoreactivity Is Regulated by ET(A) and ET(B)
Receptor Interactions. J Vasc Res. 2007;44(5):375-381.
44. Sauvageau S, Thorin E, Caron A, et al. Evaluation of
endothelin-1-induced pulmonary vasoconstriction following
myocardial infarction. Exp Biol Med (Maywood). 2006;231(6):
840-846.
45. Johnson W, Nohria A, Garrett L, et al. Contribution of
endothelin to pulmonary vascular tone under normoxic and
hypoxic conditions. Am J Physiol Heart Circ Physiol. 2002;283(2):
H568-H575.
46. Kourembanas S, McQuillan LP, Leung GK, et al. Nitric oxide
regulates the expression of vasoconstrictors and growth
factors by vascular endothelium under both normoxia and
hypoxia. J Clin Invest. 1993;92(1):99-104.
47. West JB, Mathieu-Costello O. Vulnerability of pulmonary
capillaries in heart disease. Circulation. 1995;92(3):622-631.
48. West JB, Tsukimoto K, Mathieu-Costello O, et al. Stress
failure in pulmonary capillaries. J Appl Physiol (1985).
1991;70(4):1731-1742.
49. Goggel R, Uhlig S. The inositol trisphosphate pathway
mediates platelet-activating-factor-induced pulmonary
oedema. Eur Respir J. 2005;25(5):849-857.
50. Morty RE, Kuebler WM. TRPV4: an exciting new target to
promote alveolocapillary barrier function. Am J Phys Lung Cell
Mol Phys. 2014;307(11):L817-L821.
51. Hamanaka K, Jian MY, Weber DS, et al. TRPV4 initiates the
acute calcium-dependent permeability increase during
ventilator-induced lung injury in isolated mouse lungs. Am J
Phys Lung Cell Mol Phys. 2007;293(4):L923-L932.
52. Alvarez DF, King JA, Weber D, et al. Transient receptor
potential vanilloid 4-mediated disruption of the alveolar
septal barrier: a novel mechanism of acute lung injury. Circ
Res. 2006;99(9):988-995.
53. Hummler E, Planes C. Importance of ENaC-mediated sodium
transport in alveolar fluid clearance using
genetically-engineered mice. Cell Physiol Biochem. 2010;25(1):
63-70.
54. Guazzi M, Arena R, Guazzi MD. Evolving changes in lung
interstitial fluid content after acute myocardial infarction:
mechanisms and pathophysiological correlates. Am J Physiol
Heart Circ Physiol. 2008;294(3):H1357-H1364.
55. Thorneloe KS, CheungM, BaoW, et al. An orally active TRPV4
channel blocker prevents and resolves pulmonary edema
induced by heart failure. Sci Transl Med. 2012;4(159):159ra148.
56. Jian MY, King JA, Al-Mehdi AB, et al. High vascular
pressure-induced lung injury requires P450
epoxygenase-dependent activation of TRPV4. Am J Respir Cell
Mol Biol. 2008;38(4):386-392.
57. Azzam ZS, Dumasius V, Saldias FJ, et al. Na,K-ATPase
overexpression improves alveolar fluid clearance in a rat
model of elevated left atrial pressure. Circulation. 2002;105(4):
497-501.
58. Azarbar S, Dupuis J. Lung capillary injury and repair in left
heart disease: a new target for therapy? Clin Sci (Lond).
2014;127(2):65-76.
59. Dupuis J, Guazzi M. Pathophysiology and clinical
relevance of pulmonary remodelling in pulmonary
hypertension due to left heart diseases. Can J Cardiol.
2015;31(4):416-429.
20 P R O G R E S S I N C A R D I O V A S C U L A R D I S E A S E S 5 9 ( 2 0 1 6 ) 1 1 – 2 160. Kapanci Y, Burgan S, Pietra GG, et al. Modulation of actin
isoform expression in alveolar myofibroblasts (contractile
interstitial cells) during pulmonary hypertension. Am J
Pathol. 1990;136(4):881-889.
61. Jasmin JF, Calderone A, Leung TK, et al. Lung structural
remodeling and pulmonary hypertension after myocardial
infarction: complete reversal with irbesartan. Cardiovasc Res.
2003;58(3):621-631.
62. Kingsbury MP, Huang W, Donnelly JL, et al. Structural
remodelling of lungs in chronic heart failure. Basic Res
Cardiol. 2003;98(5):295-303.
63. Chen Y, Guo H, Xu D, et al. Left ventricular failure produces
profound lung remodeling and pulmonary hypertension in
mice: heart failure causes severe lung disease. Hypertension.
2012;59(6):1170-1178.
64. Townsley MI, Fu Z, Mathieu-Costello O, et al. Pulmonary
microvascular permeability. Responses to high vascular
pressure after induction of pacing-induced heart failure in
dogs. Circ Res. 1995;77(2):317-325.
65. Townsley MI, Snell KS, Ivey CL, et al. Remodeling of lung
interstitiumbut not resistance vessels in canine pacing-induced
heart failure. J Appl Physiol. 1999;87(5):1823-1830.
66. Kerem A, Yin J, Kaestle SM, et al. Lung endothelial
dysfunction in congestive heart failure: role of impaired
Ca2+ signaling and cytoskeletal reorganization. Circ Res.
2010;106(6):1103-1116.
67. Ontkean M, Gay R, Greenberg B. Diminished
endothelium-derived relaxing factor activity in an
experimental model of chronic heart failure. Circ Res.
1991;69(4):1088-1096.
68. Staniloae C, Dupuis J, White M, et al. Reduced pulmonary
clearance of endothelin in congestive heart failure: a marker
of secondary pulmonary hypertension. J Card Fail. 2004;10(5):
427-432.
69. Lucas M, Jasmin JF, Dupuis J. Effect of ET(A) receptor
antagonist on pulmonary hypertension and vascular
reactivity in rats with congestive heart failure. Pulm
Pharmacol Ther. 2001;14(4):307-314.
70. Dupuis J, Hoeper MM. Endothelin receptor antagonists in
pulmonary arterial hypertension. Eur Respir J. 2008;31(2):
407-415.
71. McMurray JJ, Ray SG, Abdullah I, et al. Plasma endothelin in
chronic heart failure. Circulation. 1992;85(4):1374-1379.
72. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human
congestive heart failure. Circulation. 1994;89(4):1580-1586.
73. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin
correlates with the extent of pulmonary hypertension in
patients with chronic congestive heart failure [published
erratum appears in Circulation 1993 Mar;87(3):1064].
Circulation. 1992;85(2):504-509.
74. Pousset F, Isnard R, Lechat P, et al. Prognostic value of
plasma endothelin-1 in patients with chronic heart failure.
Eur Heart J. 1997;18(2):254-258.
75. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute Endothelin
A Receptor Blockade Causes Selective Pulmonary
Vasodilation in Patients With Chronic Heart Failure.
Circulation. 2000;101(25):2922-2927.
76. Baggia S, Perkins K, Greenberg B. Endothelium-dependent
relaxation is not uniformly impaired in chronic heart failure.
J Cardiovasc Pharmacol. 1997;29(3):389-396.
77. Mathew R, Wang J, Gewitz MH, et al. Congestive heart failure
alters receptor-dependent cAMP-mediated relaxation of
canine pulmonary arteries. Circulation. 1993;87(5):1722-1728.
78. Zhang CY, Ma ZS, Ma LL, et al. Effect of prostaglandin E1
inhalation on pulmonary hypertension following corrective
surgery for congenital heart disease. Exp Clin Cardiol.
2013;18(1):13-16.79. Szczeklik J, Dubiel JS, Mysik M, et al. Effects of prostaglandin
E1 on pulmonary circulation in patients with pulmonary
hypertension. Br Heart J. 1978;40(12):1397-1401.
80. Sablotzki A, Czeslick E, Schubert S, et al. Iloprost improves
hemodynamics in patients with severe chronic cardiac
failure and secondary pulmonary hypertension. Can J
Anaesth. 2002;49(10):1076-1080.
81. Hache M, Denault A, Belisle S, et al. Inhaled epoprostenol
(prostacyclin) and pulmonary hypertension before cardiac
surgery. J Thorac Cardiovasc Surg. 2003;125(3):642-649.
82. Laflamme M, Perrault LP, Carrier M, et al. Preliminary
experiencewith combined inhaledmilrinone and prostacyclin
in cardiac surgical patients with pulmonary hypertension. J
Cardiothorac Vasc Anesth. 2015;29(1):38-45.
83. Delgado JF, Conde E, Sanchez V, et al. Pulmonary vascular
remodeling in pulmonary hypertension due to chronic heart
failure. Eur J Heart Fail. 2005;7(6):1011-1016.
84. Bressollette E, Dupuis J, Bonan R, et al. Intravascular ultra-
sound assessment of pulmonary vascular disease in patients
with pulmonary hypertension. Chest. 2001;120(3):809-815.
85. Driss AB, Devaux C, Henrion D, et al. Hemodynamic stresses
induce endothelial dysfunction and remodeling of
pulmonary artery in experimental compensated heart
failure. Circulation. 2000;101(23):2764-2770.
86. Farrero M, Blanco I, Batlle M, et al. Pulmonary hypertension
is related to peripheral endothelial dysfunction in heart
failure with preserved ejection fraction. Circ Heart Fail.
2014;7(5):791-798.
87. Berridge MJ. Elementary and global aspects of calcium
signalling. J Exp Biol. 1997;200(Pt 2):315-319.
88. Firth AL, Remillard CV, Platoshyn O, et al. Functional ion
channels in human pulmonary artery smooth muscle cells:
Voltage-dependent cation channels. Pulm Circ. 2011;1(1):48-71.
89. Jeffery TK, Morrell NW. Molecular and cellular basis of
pulmonary vascular remodeling in pulmonary hypertension.
Prog Cardiovasc Dis. 2002;45(3):173-202.
90. Yin J, Hoffmann J, Kaestle SM, et al. Negative-feedback loop
attenuates hydrostatic lung edema via a cGMP-dependent
regulation of transient receptor potential vanilloid 4. Circ Res.
2008;102(8):966-974.
91. Ying X, Minamiya Y, Fu C, et al. Ca2+ waves in lung capillary
endothelium. Circ Res. 1996;79(4):898-908.
92. Kuebler WM, Ying X, Bhattacharya J. Pressure-induced
endothelial Ca(2+) oscillations in lung capillaries. Am J Phys
Lung Cell Mol Phys. 2002;282(5):L917-L923.
93. Dayeh N, Safar S, Gillis M-A, et al. TRPV4-associated
alterations of Ca2+ pulsars in a murine model of pulmonary
hypertension secondary to heart failure (1090.11). FASEB J.
2014;28(1 Supplement).
94. Dupuis J, Prefontaine A, Villeneuve L, et al. Bone
marrow-derived progenitor cells contribute to lung
remodelling after myocardial infarction. Cardiovasc Pathol.
2007;16(6):321-328.
95. Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts. I.
Paracrine cells important in health and disease. Am J Phys.
1999;277(1 Pt 1):C1-C9.
96. Lefebvre F, Prefontaine A, Calderone A, et al. Modification of
the pulmonary renin-angiotensin system and lung structur-
al remodelling in congestive heart failure. Clin Sci (Lond).
2006;111(3):217-224.
97. Chabot A, Meus MA, Naud P, et al. Nestin is a marker of lung
remodeling secondary to myocardial infarction and type I
diabetes in the rat. J Cell Physiol. 2015;230(1):170-179.
98. Chabot A, Hertig V, Boscher E, et al. Endothelial and
Epithelial Cell Transition to a Mesenchymal Phenotype Was
Delineated by Nestin Expression. J Cell Physiol. 2015;231:
1407-1627. [Pages i–i].
21P R O G R E S S I N C A R D I O V A S C U L A R D I S E A S E S 5 9 ( 2 0 1 6 ) 1 1 – 2 199. Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension
in heart failure with preserved ejection fraction: a target of
phosphodiesterase-5 inhibition in a 1-year study. Circulation.
2011;124(2):164-174.
100. Guazzi M, Samaja M, Arena R, et al. Long-term use of
sildenafil in the therapeutic management of heart failure. J
Am Coll Cardiol. 2007;50(22):2136-2144.101. Jiang BH, Tardif JC, Sauvageau S, et al. Beneficial
effects of atorvastatin on lung structural remodeling
and function in ischemic heart failure. J Card Fail.
2010;16(8):679-688.
102. Jiang BH, Tardif JC, Shi Y, et al. Bosentan does not improve
pulmonary hypertension and lung remodeling in heart
failure. Eur Respir J. 2011;37(3):578-586.
